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Referrals to the child and family centres in Renfrewshire : A comparison of
childhood psychopathology and psychosocial circumstances of affluent and deprived
areas
ABSTRACT
Objective: This paper compares childhood psychopathology and psychosocial
circumstances between two catchment areas of a Renfrewshire child service, selected for 
low and high levels of deprivation. Notions about variation of referral rates, level of multi­
agency care of children, diagnoses and severity of disturbance, based on level of 
deprivation, were investigated.
Design: Calculation of National Deprivation Scores allowed comparison of two socially 
distinct areas within Renfrewshire. A broad range of child and family psychosocial 
variables were utilised in this comparison.
Setting: Extraction of data from a NHS Child and Family Centre database.
Subjects: Data was gathered on 314 child cases referred to the child and family centre.
Results: Findings include similar referral rates between areas and greater multi-agency 
service provision for deprived areas. There was greater prevalence of child abuse and 
conduct disorder referrals from the deprived areas. In addition, there were significant 
differences in severity of disturbance, with greater disturbance found in deprived areas.
Conclusions: These results are discussed with reference to social etiological factors in 
childhood psychopathology, such as family risk factors, the implications for preventive 
interventions and need for more detailed consideration of children who adapt and cope in 
environments not conducive to mental health.
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INTRODUCTION
A long historical association links adverse circumstances and experiences to 
psychopathology. For several centuries life experiences resulting in stress have been 
considered to be direct etiological agents of disorder.1 There is epidemiological 
information that suggests that the prevalence of mental health problems in childhood and 
adolescence is increasing.2 There has been increasing attention paid to the observation that 
rates of psychiatric disorder and educational problems in children and adolescents can 
differ greatly according to area and to living circumstances.
From the wealth of research it is clear that causation of disorder in young people is 
extremely complex and multifactorial. It is well documented that children are 
psychologically at risk where there is social and cultural deprivation. It is less apparent in 
what way known etiological factors combine to result in symptoms.4 Follow-up studies 
indicate that the effect of socio-economic disadvantage and parental dysfunction are long- 
lasting.5
It is useful to know how rates of psychiatric disorder actually differ between areas. Many 
ecological studies in earlier years focused on delinquency. In recent years there has been 
increasing interest in area differences regarding emotional, behavioural and psychological 
disorders in children and adolescents. Knowledge such as this is vital if we are to deepen 
our understanding of contributing factors to these problems and guide preventative work.
There are several reasons why there may be a difference in referral rates and in the nature 
of psychiatric disorders from different areas. Families from more affluent areas are 
unlikely to be in contact with agencies such as social work, therefore, they may need to 
search quite hard for the right sort of help. Fear that their child’s problem may be a sign of 
failure on their part, may result in the problem reaching a more severe level before they 
seek help.
It could be suggested that child psychiatric referral rates are higher in lower social status 
areas. It must be asked if this difference lies in the prevalence of disorder or the likelihood 
of detection. There is an assumption that there will be more multiagency involvement in 
such an area. There are therefore potentially more people who can make a referral and the
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threshold for referral may be lower. Steinhausen and Erdin6 found that among diagnoses, 
the strongest correlations with psychosocial conditions existed for conduct disorders and 
mixed disorders of conduct and emotions. In addition, if the disorder is linked to a higher 
level of social deprivation that does not change, it is possible that children from this area 
will show a poorer outcome.
OBJECTIVES
To compare referrals to the two Child and Family Centres within Renfrewshire NHS Trust 
from an affluent area of Renfrew with a more deprived area. The following hypotheses are 
addressed by the study:
• The deprived area will have a higher incidence of referrals than the more affluent area;
• There will be less multi-agency involvement in the more affluent area and consequently 
these referrals will include individuals with a more severe problem at initial assessment;
• There will be a difference in types of referrals from the two different areas of Renfrew. 
Conduct disorders and mixed disorders of conduct and emotion will be more common 
in the more deprived area;
• There will be a difference in the type of associated abnormal psychosocial 
circumstances of the two areas. The more deprived area will be more psychosocially 
disabled on a global assessment;
• Children from the more deprived area will have a more severe disturbance on discharge 
and will be perceived by clinicians to have a poorer global outcome.
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DESIGN
Deprivation Scores have been calculated for postcode areas in the UK, which range from 
one (affluent) to seven (deprived). Referrals that had a deprivation score of one or two 
were selected to constitute the affluent Area A. Referrals that had a deprivation score of 
five or six were selected to form the more deprived Area B. (Referrals with a deprivation 
score of seven were excluded due to the very small number). Referrals from these areas to 
the Child and Family Centres between March 1st 1995 and March 1st 1996 were 
examined.
For each child, a Child and Adolescent Psychiatric Services National Audit Scorecard has 
been completed. Responses are based on referral information and interviews by the 
psychiatrist or other profession mainly involved. This information is stored in the 
department on dbase IV.
The following items were selected from the National Audit Scorecard for analysis:
• Sex;
• Stage of schooling;
• Previous referral;
• Other agency actively involved;
• Child’s carers;
• Carer’s occupation;
• Parental drug/alcohol abuse;
• Physical abuse;
• Sexual abuse;
• Emotional abuse;
• ICD-10 Axis I Clinical Psychiatric Syndromes - principle diagnosis;
• ICD-10 Axis V Associated Abnormal Psychosocial Situation;
• ICD-10 Axis VI Global Assessment of Psychosocial Disability;
• Severity of individual’s disturbance at initial assessment as diagnosed on Axis I;
• Severity of individual’s disturbance at discharge as diagnosed on Axis I;
• Global outcome of child (clinician’s rating).
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Information with regards to the population of children and young people in Argyll and 
Clyde was provided by Information Services within Renfrewshire NHS Trust.
RESULTS
(i)The Children
Information from the 1991 Census was updated in 1993 with regards to the population of 
children and young people. This information indicated that in 1993 there were 110,699 
individuals aged from 0-19 years within Argyll and Clyde. It should be noted that this 
figure includes young people aged 19 years who would not be eligible for referral to the 
Child and Family Services. In 1993 the more affluent Area A, which is comprised of 
deprivation scores one and two, included 19,750 children and young people aged 0-19 
years. The more deprived Area B, which is comprised of deprivation scores five and six, 
included 36,049 children and young people of that age.
During the specified one-year period a total of 314 National Audit Scorecards were 
completed for children seen by clinicians. Of the 109 referred from Area A, 56 (51%) 
were male and 53 (49%) were female. Of the 205 referred from Area B, 120 (58%) were 
male and 85 (42%) were female.
The above information on population size was used to estimate the referral rate from the 
two areas. Both Area A and Area B had a referral rate of 0.6% from the child population.
The majority of children referred from both areas were of primary school age (Area 
A=43%, Area B=46%) and secondary school age (Area A=45%, Area B=38%). Eight 
percent of children from Area A were of pre-school age, as were 15% from Area B.
Twenty seven percent of children from Area A and 28% from Area B had previously been 
referred to this service. Five percent from Area A and 4% from Area B had previously 
been referred to another psychiatric or psychological service.
Other agencies were actively involved with 30% and 46% of children from Area A and
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Area B respectively.
(ii) The Parents/Carers
Insert Table 1. here.
As described in Table 1. (see Appendix 1.2), most children from Area A were cared for by 
both parents. In Area B most children were cared for by either a single parent, one parent 
plus another adult or some other adult(s).
Insert Table 2. here.
Table 2.(see Appendix 1.2) shows that more male and female carers were unemployed in 
Area B than Area A, as indicated by the National Audit Scorecard.
In Area A, 6% of parents/carers abused drugs and/or alcohol compared to 11% of 
parents/carers from Area B, as indicated by the National Audit Scorecard.
(iii) The Difficulties Children Experienced
Four percent of children from Area A were known to have been physically abused, 
compared with 6% from Area B. This result did not reach statistical significance (X =3.53, 
df=l, p>.05). Six percent were known to have been sexually abused from Area A in 
comparison to 11% from Area B. Again, this result did not reach statistical significance 
.34, df=l, p> 05). None of the children from Area A were known to have been 
emotionally abused. However, 8% of children from Area B were known to have been 
emotionally abused. This association between area and emotional abuse was found to be 
significant (X =5, df=l, p< 05). Children could be abused in more than one way.
Insert Table 3. here.
If a clinical classification was appropriate, this was made using ICD-10 Axis I for Clinical 
Psychiatric Syndromes.7 The most frequent principal diagnoses are detailed in Table 3. 
(see Appendix 1.2)
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More children from Area A than Area B had no clinical psychiatric syndromes. Conduct 
disorders and mixed disorders of conduct and emotion, were the most frequently diagnosed 
for Area A and Area B; Area B had a higher percentage of diagnoses concentrated in these 
disorders. Emotional disorders were more equally diagnosed between the two groups. 
Mood and adjustment disorders were more common for Area A.
Insert Table 4. here.
Table 4. (see Appendix 1.2) describes the severity of the individual’s disturbance at both 
initial assessment and discharge, as diagnosed on Axis I. At initial assessment, 46% of 
children from Area A were deemed ‘psychologically normal’ or experiencing ‘trivial or 
minor abnormalities only’, compared to 32% from Area B. Area B referrals revealed that 
68% of children were experiencing ‘slight’, ‘moderate’ or ‘marked’ disorders in 
comparison to 54% from Area A. This association between area and the severity of 
disturbance at initial assessment was found to be significant (X =6.29, df=l, p< 05).
(iv) Associated Abnormal Psychosocial Situation
Insert Table 5. here.
The most frequent principle abnormal psychosocial situation for both Area A and Area B 
was ‘Abnormal family relationships’, followed by ‘Abnormal qualities of upbringing’ and 
‘Mental disorder within the family’. ‘Abnormal immediate environment’ and ‘acute life 
events’ were the next most frequent categories for both areas (see Appendix 1.2).
Insert Table 6. here.
Table 6. (see Appendix 1.2) describes ICD-10 Axis VI Global Assessment of Psychosocial 
Disability. Sixty percent of referrals from Area A fell within the ‘normal’ to ‘moderate 
functioning’ range, compared to 41% of referrals from Area B. Forty percent of referrals 
from Area A fell within the ‘slight to serious disability’ categories compared to 56% of 
Area B. This association between area and degree of psychosocial disability was found to 
be highly significant (X =8.56, df=l, p< 01).
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(v) Outcome
At discharge, as detailed in Table 4., 58% of children from Area A were considered 
‘psychologically normal’ or experiencing ‘trivial’ or ‘minor abnormalities only’ compared 
to 14% from Area B. Twenty percent of children from Area A continued to experience 
‘slight’, ‘moderate’, or ‘marked’ disorder compared to 56% of Area B.
Clinicians gave children a ‘Global outcome rating’ where applicable as described in Table
7. (see Appendix 1.2). Eighteen percent of children from both areas showed ‘no change’. 
Nine percent from both areas were ‘slightly improved’. Twenty-five percent from Area A 
and 29% from Area B were considered to have ‘improved’. Seventeen percent from Area 
A and 11% from Area B were deemed ‘much improved’. Six percent from Area A had 
‘recovered’, compared with 1% from Area B. Again, it is noted that a substantial 
proportion of the information was ‘missing or unknown’.
CONCLUSIONS
The first hypothesis that the more deprived Area B would have a higher incidence of 
referrals than the more affluent Area A, was not supported when the size of the population 
of children and young people was taken into account. Both areas had the same incidence 
of referrals. One possible explanation for this is that the agencies involved are likely to be 
in contact with the families in greatest need or with children experiencing the greatest 
difficulties. It is possible that there are families and children whose difficulties are of a 
less severe nature and who consequently do not come to the attention of a potential 
referring agent. In addition, this study does not take into account the resources and 
services that are available locally for families.
The second hypothesis that there would be less multi-agency involvement in the more 
affluent Area A was supported. This hypothesis also stated that individuals from Area A 
would present with a more severe problem as a result of less multi-agency involvement. 
This was not found to be the case. Children from Area B were experiencing significantly 
more ‘slight’, ‘moderate’ and ‘marked’ disorders at initial assessment. Therefore, although 
there is more multi-agency involvement in Area B and presumably an increased likelihood
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of detection, children from Area B present with a more severe disturbance at initial 
assessment. Possible reasons for this become apparent when risk factors, which these 
children are subjected to, are discussed.
The third hypothesis asserted that there would be a difference in types of referral from the 
two areas. Specifically, conduct disorders and mixed disorders of conduct and emotion are 
more common in the more deprived area. However, it was found that conduct disorders 
and mixed disorders of conduct and emotion were the most frequent principle diagnosis for 
both areas. The difference was that a greater percentage of children from Area B were 
represented by these disorders. Berelowitz and Nelki8 note that conduct disorders are 
much more common in boys and that children tend to come from a disadvantaged 
background; which could explain this finding. More children from Area A did not have a 
diagnosed psychiatric syndrome.
The fourth hypothesis stated that there would be a difference in the type of associated 
abnormal psychosocial circumstances of the two areas and that the more deprived area 
would be more psychosocially disabled on a global assessment. The results indicate that 
both areas share the same type of psychosocial characteristics. However, the ICD-10 
Global Assessment of Psychosocial Disability7 distinguishes between the two areas in that 
a significantly greater proportion from Area B fall within the ‘disability’ categories.
The fifth hypothesis maintained that children from Area B would have a more severe 
disturbance on discharge. In addition, it was postulated that children from Area B would 
be perceived by the clinicians to have a poorer Global Outcome. Although Farrington3 
states that the impact of socio-economic disadvantage and parental dysfunction has long- 
lasting negative effects, conclusions cannot be drawn due to the substantial proportion of 
data missing or unknown.
Additional information allows consideration of possible reasons for differences between 
Area A and Area B. Pearce9 recognises that there are ‘child risk factors’ which include 
genetic influences, specific developmental delay, difficult temperament and physical 
illness among others. He also identifies ‘family risk factors’ which include family 
breakdown, physical, sexual, and emotional abuse, parental drug and alcohol abuse; all of 
which have been demonstrated to be more frequent in Area B, putting these children at
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increased risk.
Pearce also details ‘environmental risk factors’ which includes socio-economic 
disadvantage which children from Area B experience to a greater extent. This situation is 
likely when carers are unemployed, divorced or living alone. Again, all of these situations 
are more frequently found in referrals from Area B.
Stone and Koupemik10 maintain that “where social and cultural deprivation exist, children 
are psychologically at risk” as has been demonstrated in this study. Williams and 
Richardson2 state that no one profession or agency alone can hope to comprehend all the 
issues or be responsible for every response. It is essential that children’s mental health and 
social problems are met with close collaboration between a wide variety of agencies.
It is vital to recognise that there are characteristics of certain environments which will put 
children at risk and of certain adults which predict that they will have difficulty parenting. 
This would suggest that children vulnerable to mental health problems could be identified 
prior to birth, which highlights the need for preventative work.
Several authors11 have noted that many children who suffer adverse circumstances and risk 
factors do not actually develop problems or disorders. Factors such as self- esteem, 
sociability, absence of parental discord and social support systems protect children. As 
professionals we have much to learn from children who cope, and even flourish, in adverse 
circumstances. This is an area for further essential research.
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Should symptomatically hypothyroid but biochemically euthyroid patients be treated
with thyroxine? : A review
Abstract
There is a wealth of literature regarding the treatment, psychiatric and neuropsychological 
concomitants of clinical and subclinical hypothyroidism. However, polarised arguments 
about the utility of treating patients who are symptomatically hypothyroid, but 
biochemically euthyroid have recently occurred, in the absence of any clinical trials. This 
review highlights current scientific understanding concerning the treatment of hypothyroid 
disorders. In addition, the need for a scientific clinical treatment trial to establish whether 
symptomatically hypothyroid, but biochemically euthyroid patients should be treated with 
thyroxine is emphasised.
Key Words: Symptomatically Hypothyroid, Biochemically Euthyroid, Double-blind, 
Placebo Controlled, Treatment Outcome Trial, Thyroxine, Cognitive Function, 
Psychological Health
Introduction
The thyroid is the ductless gland found on both sides of the trachea. It secretes 
predominantly thyroxine (T4), and a small amount of triiodothyronine (T3). Production of 
T3 and T4 in the thyroid is stimulated by thyrotrophin (thyroid-stimulating hormone, 
TSH). Ingbar and Woeber1 state that the thyroid hormones play upon a great multiplicity 
of metabolic processes: influencing the concentration and activity of numerous enzymes;
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the metabolism of substrates, vitamins and minerals; the secretion and degradation rates of 
virtually all other hormones; and the response of their target tissues to them. As a 
consequence, it can truly be said that no tissue or organ system escapes the adverse effects 
of thyroid hormone excess or insufficiency. Hypothyroidism is the result of structural or 
functional abnormalities of the thyroid gland leading to thyroid hormone deficiency. It is 
therefore characterised by a raised TSH and a low level of T4. Subclinical hypothyroidism 
is defined as an elevated resting level of TSH in the context of normal T4. Euthyroid is the 
term applied when thyroid function tests, including TSH are within the reference range.
Recently, there has been increasing interest in a group of patients who present as 
symptomatically hypothyroid but biochemically euthyroid. This review will consider 
whether these patients should be considered for thyroxine replacement treatment. Firstly, 
the literature regarding the clinical features, psychiatric and neuropsychological 
manifestations of clinical hypothyroidism will be discussed. Secondly, the same areas will 
be reviewed in relation to subclinical hypothyroidism. Thirdly, the treatment of clinical 
hypothyroidism and subclinical hypothyroidism will be considered. Finally, the current 
debate concerning thyroxine replacement in symptomatically hypothyroid, but 
biochemically euthyroid patients will be outlined.
Clinical Hypothyroidism
Clinical features associated with hypothyroidism include tiredness, lethargy, weight gain, 
coarsening of the skin, intolerance to cold, hair loss, dry hair, hypersomnolence and 
delayed reflexes.2 Several authors argue that the non-specific nature of the signs and
16
symptoms of hypothyroidism means that biochemical tests of thyroid function (specifically 
TSH) are an essential component of the diagnosis.3,4
Psychiatric symptoms are reported to be a common clinical complication of thyroid 
disorders.5,6 Hypothyroidism has long been known to induce mania, dementia and 
dementia like features. In particular, it has frequently been described as accompanied by
7 odepressive symptoms. Haggerty and Prange report that almost 100% of patients with 
severe hypothyroidism are found to have serious concurrent depression. Whybrow and 
Ferral5 reported that in a group of seven hypothyroid patients the predominant affective 
disturbance was a marked depression of mood. Jain9 assessed 30 consecutive patients 
diagnosed as hypothyroid and judged 13 patients to be clinically depressed.
In addition, patients who are hypothyroid have been reported to suffer from impairment of 
cognitive functions, such as recent memory, attention, inability to concentrate and mental 
slowing.10,11 Osterweil, Syndulko, Cohen et al.12 concluded that hypothyroidism in non­
demented older adults is associated with impairments in learning, word fluency, visual- 
spatial abilities, and some aspects of attention, visual scanning and motor speed. Leentjens
13and Kappers add lack of initiative to the list of affected cognitive symptoms and 
Mennemeier, Gamer, Heilman et al.14 include problem solving abilities. Denicoff, Russel, 
Lakshmanan et al.10 state that the capacity to perform simple calculations is impaired.
Subclinical Hypothyroidism
Jaeschke, Guyatt, Gerstein et al.15 found that patients with subclinical hypothyroidism
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experienced similar symptoms to those with hypothyroidism: physical complaints; 
reduction in energy and well being; disturbance of mood and emotions; and deficits in 
cognitive functions.
To elaborate, evidence indicates that subclinical hypothyroidism may be a risk factor for 
depression.8 This idea was initially put forward by studies which examined rates of thyroid 
laboratory abnormalities in psychiatric patients. Subclinical hypothyroidism has been 
found in 5-15% of depressed patients.16,17,18 Antithyroid antibodies have been found in 9- 
20% of depressed psychiatric patients.19,20 The rates of thyroid laboratory abnormalities in 
all of these studies were high compared with reported population norms. However, most 
studies did not use control groups, which represents an important weakness because the 
prevalence of thyroid dysfunction is highly influenced by age and gender. The one 
controlled study to date, compared age and sex controlled antibody rates in psychiatric 
inpatients and general medical outpatients and found an elevated rate of antithyroid 
antibodies in subjects with bipolar depression, but not in those with unipolar depression.21
Only recently have studies been conducted in which psychiatric evaluations were 
performed in specified groups of patients with endocrine disorders. To date, such data 
strengthen the less well-controlled findings from psychiatric subjects. Haggerty, 
Marquardt, McAllister et al22 screened thyroid function in 148 general medical patients and 
found a history of treatment for depression in 50% of those with higher TSH values 
compared with 18% of those with lower TSH values. In a second study by Haggerty, 
Stem, Mason et al.23, blind psychiatric assessments with structured diagnostic interviews 
revealed a nearly threefold higher lifetime prevalence of depression in those with 
subclinical hypothyroidism (56%) than those found to be euthyroid (18%). In geriatric
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populations the association appears to be even more striking. Esposito, Haggerty, Stem et 
al.24 examined routinely obtained laboratory data on 163 patients over the age of 65 who 
were followed in a geriatric medical evaluation clinic. Of these, 9% had thyroid function 
test results consistent with the diagnosis of subclinical hypothyroidism. Seventy-five 
percent of patients had a lifetime history of major depression, compared with 18% of 
euthyroid patients.
Haggerty and Prange8 conclude that, in contrast to overt hypothyroidism, subclinical 
hypothyroidism is probably not a sufficient cause of depression. Rather it may work in 
concert with other risk factors to increase the likelihood that episodes of this recurrent 
disorder will occur when, and if, other vulnerability factors are also present.
Monzani, Del Guerra, Caraccio et al.7 note that only scant data is available concerning 
neuropsychological abnormalities in subclinical hypothyroidism. These authors assessed 
selected neuropsychological features by means of standardised tests in a group of patients 
with subclinical hypothyroidism who were free from subjective neuropsychological 
complaints. Significant impairment was demonstrated in patient’s memory-related 
abilities, namely short-term memory, digit span and visual memory. However, it should be 
noted that this study has a small sample size (n=14) and the researchers were not blind to 
the treatment received by the patients. Jaeschke at al.15 established that with regards to 
cognitive function, patients with subclinical hypothyroidism displayed difficulties in 
remembering and felt mentally slower. No control group was used in this study. Haggerty, 
Stem, Beckwith et al. state that subjects with subclinical hypothyroidism tend to perform 
more poorly than euthyroid subjects on measures of verbal recall, visuospatial recall and 
attention. These findings are reported to parallel data from clinical populations indicating
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that subclinical hypothyroidism may have important neuropsychiatric consequences.
Benefits of Thyroid Replacement in Clinical Hypothyroidism and Subclinical 
Hypothyroidism
Jaeschke et al.15 state that thyroid replacement is clearly beneficial once T4 falls (overt 
hypothyroidism). Thyroid hormone replacement therapy appears to be associated with 
improvements in mood.26,10,27 Improved functioning has been shown in selected areas of 
cognitive function such as attention, concentration, learning, retention and word fluency.12 
However, although a control group was employed the study did not include a placebo. 
Mennemeier, Gamer and Heilman14 state that the link between replacement therapy and 
improved cognitive functions is tentative. It has been argued by some that the cognitive 
symptoms due to hypothyroidism may not be reversible.13,14 They report that only a few 
studies used unselected patient populations and psychological tests to assess
on  i n  o s  oqcognition. ’ ’ ’ Two noted improvements in general intelligence following 
treatment.27,28 Two others found no change in non-verbal intelligence, attention, or general 
cognitive function.10,29 No study used a combination of treatment design and control 
subjects which was adequate to rule out practice effects, nor did any study use detailed 
neuropsychological tests of intelligence or memory.
Jaeschke et al.15 state that thyroid replacement for patients with subclinical hypothyroidism 
remains controversial. Haggerty et a l25 argue that while there is some evidence for long­
term health consequences of subclinical hypothyroidism, we do not yet know enough about 
the relative risks versus benefits of long-term thyroid hormone administration in this
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disorder to justify routine treatment in all cases. However, these authors add that there is 
good reason to consider a trial of thyroid hormone treatment for cases of subclinical 
hypothyroidism that are accompanied either by mood or energy changes or by treatment 
resistant major affective disorder.
Thyroid hormone has been shown to reverse depressive symptomatology in patients with 
subclinical hypothyroidism.30 Two double-blind trials in patients with subclinical 
hypothyroidism have shown that, after treatment with thyroxine, target organ function may 
improve and there may be a greater sense of well-being in some but by no means all.31 
However, Beckett and Toft32 report that the consensus is that patients with subclinical 
hypothyroidism should be treated with thyroxine.
Weetman4 summarises the few recent neuropsychological studies of patients with 
subclinical hypothyroidism. One small crossover trial has indicated that thyroxine 
improves symptom scores (including mental lethargy) and psychometric performance 
compared with a placebo in 20% of women.33 However, there are a number of difficulties 
with this study: there was no control group; they did not utilise a comprehensive set of 
psychometric tests; the study design did not include a wash-out period, which means that 
there is the risk of a carryover effect of the first drug into the second treatment period; and 
finally, the placebo was prescribed in a different manner to thyroxine. Although the above 
study has limitations, the improvements in functioning reported are supported by a study 
which included patients previously treated for hyperthyroidism31 and by a prospective, 
unblinded trial of thyroxine in patients with subclinical hypothyroidism.7 This latter study 
found an improvement in memory skills. Jaeshke et al.15 found a statistically significant 
improvement in a composite memory score in actively treated patients with subclinical
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hypothyroidism versus controls. However, the method of deriving this composite memory 
is unclear.
Symptomatically Hypothyroid but Biochemically Euthyroid Patients: The Current 
Debate
In the past two years there has been vehement debate in the field of thyroid disease. 
Skinner, Thomas, Taylor et al.34 have questioned current medical practice stating that they 
considered it to be incorrect that “normal” free thyroxine and thyroid stimulating hormone 
concentrations negate the diagnosis of hypothyroidism. They also reported that it is 
unusual for doctors to start thyroxine replacement in clinically hypothyroid but 
biochemically euthyroid patients. However, it is their belief that the exclusion of 
hypothyroidism on the grounds of hormone concentrations measured in the laboratory 
seems wrong and that many patients are condemned to years of hypothyroidism with its 
pathological complications and poor quality of life. Skinner et al.34 have urged that the 
question of biochemically euthyroid patients should be subjected to a formal clinical trial.
Shepherd35 reported that he was aware of a number of patients with normal thyroid 
function being given a daily dose of thyroxine mainly as a result of publicity being given in 
the lay media36 to the hypothesis put forward by Skinner.34 Shepherd35 is concerned that 
not only are patients continuing to be prescribed thyroxine, but in some cases the dose is 
being progressively increased. He outlines possible detrimental consequences.
Beckett and Toft32 speculate that because autoimmune thyroid disease is common, it is
22
possible that reference ranges were calculated from populations containing patients with a 
degree of thyroid failure and that the true upper limit for normal serum thyroid stimulating 
hormone concentrations may be slightly lower than 5mU/l. They highlight the fact that 
there are no studies of the effect of thyroxine in patients with non-specific symptoms and 
hormone concentrations below 5mU/l, and until there is objective evidence of benefit, it 
would be unwise to support the views of Skinner et al.34 Beckett and Toft32 believe that it 
is unlikely, from clinical experience, that there will be evidence of benefit and that many 
patients would gain a placebo effect.
Beckett and Toft , Beastall and Thomson and Shepherd , have urged that in the absence 
of any reputable evidence to support the hypothesis that clinical hypothyroidism can exist 
in biochemically euthyroid patients, this speculative use of thyroxine should be restricted 
to a carefully supervised trial.
McLaren, Kelly and Pollock38 report that several symptomatically hypothyroid but 
biochemically euthyroid patients referred to a clinic following the recent publicity, 
complained of considerable reduction in their quality of life which had not been helped by 
other measures. Two patients reported a marked improvement in their condition following 
thyroxine treatment. These authors acknowledge that this result could have been due to a 
placebo response and that our present state of knowledge suggests that there is no scientific 
justification for this treatment. However, they argued that it cannot be assumed that 
everything is known about the physiology of thyroid secretion and its controlling 
hormones, or the pharmacological effects of exogenous thyroxine.32 In view of the lack of 
effective treatment for this group, further investigation of the effect of thyroxine is 
justified.38
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Conclusions
To date, there is evidence that hypothyroidism and subclinical hypothyroidism result in 
physical complaints, reduction in energy and well-being, disturbance of mood and 
emotions and deficits in cognitive functions. Although research on the effects of active 
treatment on some of these areas is limited, there is evidence to suggest that thyroxine 
replacement can lead to improvements. It is evident that further research is required to 
provide evidence that either thyroxine is truly effective in patients who may be clinically 
hypothyroid but are biochemically euthyroid, or, that any improvement seen is due to a 
placebo effect.
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Thyroxine replacement in symptomatically hypothyroid but biochemically euthyroid 
patients: Is it effective?
SUMMARY
The clinical features of hypothyroidism are non-specific and biochemical tests of thyroid 
function are considered essential for diagnosis. Recent articles in the local press have 
suggested that there are a large number of patients who are clinically hypothyroid but 
biochemically euthyroid and who would benefit from thyroxine replacement (Reid, 1997). 
This has led to correspondence in the British Medical Journal (Beastall and Thompson, 
1997; Beckett and Toft, 1997; McLaren, Kelly and Pollock, 1997; Shepherd, 1997; Skinner, 
Thomas, Taylor et al., 1997). In the absence of any reputable evidence, it is unlikely that 
there are patients who are clinically hypothyroid but biochemically euthyroid. However, a 
properly controlled trial is required. This is a randomised, double blind, crossover, placebo- 
controlled trial to investigate the efficacy of thyroxine replacement in a group of such 
patients. Twenty-two patients and nineteen control subjects will take part in the study at 
Stobhill General Hospital. Standardised psychological self-rating questionnaires and 
objective neuropsychological tests will determine the efficacy of thyroxine treatment.
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INTRODUCTION
The thyroid is the ductless gland found on both sides of the trachea. It secretes thyroxine 
(T4) that controls the rate of metabolism. Hypothyroidism is the result of structural or 
functional abnormalities of the thyroid gland leading to thyroid hormone deficiency. It is 
therefore, characterised by a raised thyroid stimulating hormone (TSH) and a low level of 
thyroxine. Subclinical hypothyroidism is defined as an elevated resting level of thyroid 
stimulating hormone in the context of normal thyroxine.
Clinical features associated with hypothyroidism include: tiredness; lethargy; weight gain; 
coarsening of the skin; intolerance to cold; hair loss; dry hair; hypersomnolence; and delayed 
reflexes. Several authors have argued that the non-specific nature of the signs and 
symptoms of hypothyroidism means that biochemical tests of thyroid function (specifically 
TSH) are an essential component of the diagnosis (e.g., Vanderpump, Ahlquist, Franklyn et 
al., 1996; Weetman, 1997). Psychiatric symptoms are reported to be a common clinical 
complication of thyroid disorders (Whybrow and Ferral, 1974). In particular, 
hypothyroidism has frequently been described as accompanied by depressive symptoms 
(Monzani, Del Guerra, Caraccio et al., 1993). In addition, patients who are hypothyroid 
have been reported to suffer from impairment of cognitive functions, such as recent 
memory, attention, inability to concentrate and mental slowing (Denicoff, Russell, Joffe et 
al., 1990; McGregor, 1996).
Jaeschke, Guyatt, Gerstein et al. (1996) found that patients with subclinical hypothyroidism 
experienced similar symptoms to those with hypothyroidism: physical complaints; reduction 
in energy and wellbeing; disturbance of mood and emotions; and deficits in cognitive
34
function.
Jaeschke et al. (1996) stated that thyroid replacement is clearly beneficial once T4 falls 
(overt hypothyroidism) but that thyroid replacement for patients with subclinical 
hypothyroidism remains controversial. However, Beckett and Tofl (1997) reported that the 
consensus is that patients with subclinical hypothyroidism should be treated with thyroxine. 
One double-blind trial in patients with subclinical hypothyroidism have shown that, after 
treatment with thyroxine, target organ function may improve and there may be a greater 
sense of wellbeing in some, but by no means all patients (Cooper, Halpem, Wood et al., 
1984). Thyroid hormone has been shown to reverse depressive symptoms in patients with 
subclinical hypothyroidism (Goodnick, Extein and Gold, 1989).
In recent years, few studies have assessed the benefit of thyroid replacement therapy on 
cognitive function in hypothyroidism, but improved functioning has been shown in selected 
areas such as attention, concentration, learning, retention and word fluency (Osterweil, 
Syndulko, Cohen et al., 1992).
Weetman (1997) summarised the few recent neuropsychological studies of patients with 
subclinical hypothyroidism. One small crossover trial has indicated that thyroxine improves 
symptom scores (including mental lethargy) and psychometric performance compared with 
a placebo in 20% of women (Nystrome, Caidahl, Fager et al., 1988). This trial is supported 
by a study which included patients previously treated for hyperthyroidism (Cooper, 1984) 
and by a prospective, unblinded trial of thyroxine in patients with subclinical hypothyroidism 
(Monzani et al., 1993). This latter study found an improvement in memory skills. Jaeshke 
et al. (1996) found a statistically significant improvement in a composite memory score in
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actively treated patients with subclinical hypothyroid versus controls.
In the past two years there has been vehement debate in the field of thyroid disease. 
Skinner et al (1997) stated that it is unusual for doctors to start thyroxine replacement in 
clinically hypothyroid but biochemically euthyroid patients. However, he reported that the 
exclusion of hypothyroidism on the grounds of hormone concentrations measured in the 
laboratory seems wrong and that many patients are condemned to years of hypothyroidism 
with its pathological complications and poor quality of life.
Shepherd (1997) reported that he was aware of a number of patients with normal thyroid 
function being given a daily dose of thyroxine mainly as a result of publicity being given in 
the lay media (Reid, 1997) to the hypothesis put forward by Skinner (1997). Several 
authors have urged that in the absence of any reputable evidence to support the hypothesis 
that clinical hypothyroidism can exist in biochemically euthyroid patients, the speculative 
use of thyroxine should be restricted to a carefully supervised trial (Beastall, 1997; Beckett 
and Toft, 1997; Shepherd, 1997).
McLaren, Kelly and Pollock (1997) stated that patients reporting a considerable 
improvement after thyroxine treatment could be due to a placebo response. However, they 
argued that it cannot be assumed that everything is known about the physiology of thyroid 
secretion and its controlling hormones, or the pharmacological effects of exogenous 
thyroxine (Beckett and Toft, 1997).
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AIM OF THE STUDY
The aim of this study is to determine whether thyroxine treatment has an effect on the 
cognitive functioning, psychological and physical wellbeing of patients who are 
symptomatically hypothyroid but biochemically euthyroid.
PLAN OF INVESTIGATION 
Subjects
The trial will involve 22 patients between the ages of 22 and 73 years. Patients will be 
recruited following referral by their General Practitioner, other clinicians, or by self-referral 
following newspaper publicity (Appendix 3.1). They will be considered for the study if, for 
a period of at least the previous six months, they have exhibited at least three of the 
following signs and symptoms for which no other cause can be elicited: tiredness; lethargy; 
weight gain or inability to lose weight; cold intolerance; hair loss; and dry skin or dry hair. 
All patients will have thyroid function tests, including TSH, within the reference range. 
Persons with known cardiovascular disease, hepato/renal failure, pregnancy or thyroid 
dysfunction will be excluded. The trial will involve 19 age and sex matched control subjects 
who will be normal volunteers.
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Measures
Biochemical
The medical team will assess the following:
At Baseline; Thyroid stimulating hormone (TSH); thyrotrophin-releasing hormone (TRH); 
thyroxine (T4); triiodothyronine (T3); free thyroxine (FT4); anti-thyroid peroxidase; anti- 
thyroglobulin antibodies; prolactin; cholesterol; lipids; full blood count; electrolytes; liver 
function; weight; blood pressure; and pulse.
At Weeks 12 and 30; Free T4 (FT4); prolactin; cholesterol; weight; blood pressure; and 
pulse.
Psychological Assessment Measures
The following psychological assessment measures will be administered at baseline and 
repeated at weeks 12 and 30, to assess quality of life concepts: Hospital Anxiety and 
Depression Scale (HADS; Zigmund and Snaith, 1983); Social Functioning Questionnaire 
(SF-36; Ware, 1997); and the Fatigue Scale (Chalder, 1993). A number of cognitive tests 
will also be administered: the Digit Span, Logical Memory, Visual Reproduction and Verbal 
Paired Associates subtests from the Wechsler Memory Scale - Revised (WMS-R; Wechsler, 
1987); and Trail Making Test (Reitan, 1966). A description of each assessment measure is 
given in Appendix 3.2.
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Design and Procedure
This is a randomised, double blind, crossover, placebo-controlled trial. Subjects who agree 
to take part in the study will be given an information sheet and will be asked to sign a 
consent form (see Appendix 3.3). Participants in the study will be randomised at the first 
clinic visit. Each group (patients and controls) will receive placebo or lOOpg thyroxine for 
three months followed by a six-week washout period. They will then crossover and receive 
a further three months of treatment (either thyroxine or placebo). The Pharmacy 
Department who will hold the key to the randomisation will dispense the drugs.
Setting and equipment
Patients will be assessed at Stobhill General Hospital. For the psychological component of 
the study, the appropriate questionnaires, materials and scoring sheets for the WMS-R 
subtests and Trail Making Test will be required.
Data analysis
Data will be collated first on a paper summary sheet for each individual and than transferred 
to a database. Statistical analyses will involve independent t-tests and paired t-tests.
PRACTICAL APPLICATIONS
In response to recent correspondence in the British Medical Journal from a number of
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eminent practitioners in the field of thyroid disease and the considerable demand for 
treatment, this study will provide evidence as to whether thyroxine treatment is effective in 
symptomatically hypothyroid but biochemically euthyroid patients.
TIMESCALES
The placebo is scheduled to be available from February 1998. No difficulty is anticipated 
with recruitment of subjects given local interest. Data collection will be complete seven 
months after the inclusion of the final subject.
ETHICAL APPROVAL
The study has received ethical approval from the Stobhill General Hospital Ethics 
Committee.
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Thyroxine replacement in symptomatically hypothyroid but biochemically euthyroid
patients: Is it effective?
Abstract
Background The treatment of patients who present as symptomatically hypothyroid but 
biochemically euthyroid is the subject of current debate. Accepted medical practice has 
been questioned, with the assertion that it is incorrect that normal thyroid function tests 
negate the diagnosis of hypothyroidism.1 Some of these patients have been treated with 
thyroxine in the absence of any experimental trials.2 This is the first known trial to
investigate whether thyroxine treatment has an effect on the cognitive functioning,
psychological and physical wellbeing of patients who are symptomatically hypothyroid but
biochemically euthyroid.
Methods This study compared 22 symptomatically hypothyroid but biochemically euthyroid
patients’ and 19 matched control subjects’ responses to thyroxine, in a randomised, double
47
blind, crossover, placebo-controlled, trial. A range of standardised biochemical and 
psychological measures were employed at baseline, prior to random allocation to thyroxine 
or placebo. Assessment measures were repeated at the end of both 12-week treatment 
periods. There was a six-week washout period between treatments.
Results At baseline, patients were significantly more impaired than control subjects on the 
majority of psychological and cognitive measures. Thyroxine treatment did not have a 
significant beneficial effect on the cognitive functioning, psychological and physical 
wellbeing of patients who were symptomatically hypothyroid but biochemically euthyroid.
Conclusions Symptomatically hypothyroid but biochemically euthyroid patients do not 
benefit from treatment with thyroxine. It is suggested that on the basis of this evidence, 
there is no justification for the routine prescription of thyroxine.
Key Words: Symptomatically Hypothyroid, Biochemically Euthyroid, Double-blind, 
Placebo Controlled, Treatment Outcome Trial, Thyroxine, Cognitive Function, 
Psychological Health.
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Introduction
In the past two years there has been vehement debate in the field of thyroid disease
concerning the treatment of patients who present as symptomatically hypothyroid but are
biochemically euthyroid, i.e., they have the non-specific features of hypothyroidism but their 
thyroid function tests are within the reference range. Skinner, Thomas, Taylor et al.1 have
questioned current medical practice, stating that the exclusion of hypothyroidism on the
grounds of hormone concentrations measured in the laboratory is wrong and that many
patients are condemned to years of hypothyroidism with its pathological complications and 
poor quality of life. Shepherd2 reported that he was aware of a number of patients with
normal thyroid function being given a daily dose of thyroxine (T4) mainly as a result of 
publicity in the lay media3 to the hypothesis put forward by Skinner, Thomas, Taylor et al.1 
Shepherd2 was concerned that not only were patients continuing to be prescribed thyroxine,
but in some cases the dose was being progressively increased. He outlined possible
detrimental consequences, for instance, there could be increased strain on the heart or 
osteoporosis might develop. McLaren, Kelly and Pollock4 reported that two
symptomatically hypothyroid but biochemically euthyroid patients, not helped by any
previous treatment, reported a marked improvement in their condition following thyroxine
treatment. They acknowledged that improvements could have been due to a placebo effect
and that the present state of knowledge suggested that there was no scientific justification
for such treatment.
Descriptions of the thyroid gland, hypothyroidism and subclinical hypothyroidism disorders
are given in Chapter 2 (Major Project Literature Review). Clinical features associated with
hypothyroidism include: tiredness; lethargy; weight gain; coarsening of the skin; intolerance 
to cold; hair loss; dry hair; hypersomnolence; and delayed reflexes. Psychiatric symptoms 
are reported to be a common clinical complication of thyroid disorders.5 In particular, 
hypothyroidism has frequently been described as accompanied by depressive symptoms.6 In
addition, patients who are hypothyroid have been reported to suffer from impairment of
cognitive functions, such as recent memory, attention, inability to concentrate and mental 
slowing.7,8 Jaeschke, Guyatt, Gertein et al.9 found that patients with subclinical
hypothyroidism experienced similar symptoms to those with hypothyroidism: physical
complaints; reduction in energy and wellbeing; disturbance of mood and emotions; and
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deficits in cognitive function.
Jaeschke, Guyatt, Gertein et al.9 stated that thyroid replacement is clearly beneficial once T4
falls below the lower limit of the reference range (overt hypothyroidism), with some
evidence of improvements in mood and selected areas of cognitive function. There is also
evidence of similar improvements in patients with subclinical hypothyroidism following
treatment with thyroxine, although some of the studies have methodological difficulties.
(See Chapter 2, Major Research Project Literature Review, for a full discussion). To date,
there have been no experimental studies that have assessed the effect of thyroxine on
symptomatically hypothyroid but biochemically euthyroid patients.
Several authors have urged that in the absence of any reputable evidence to support the
hypothesis that clinical hypothyroidism can exist in biochemically euthyroid patients, the 
speculative use of thyroxine should be restricted to a carefully supervised trial.2,10,11 The
aim of this randomised, double blind, placebo-controlled trial was to determine whether
treatment with thyroxine had an effect on the cognitive functioning, psychological and
physical wellbeing of patients who were symptomatically hypothyroid but biochemically
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euthyroid.
Methods
Subjects
Patients and control subjects were invited to participate in a randomised, double blind, 
crossover, placebo-controlled study. The research was conducted at Stobhill General 
Hospital, Glasgow. The Stobhill General Hospital Ethical Committee approved the study. 
Each participant was provided with an information sheet and gave written consent 
(Appendix 3.3). Data collection commenced on March 6th 1998 and was completed on 26th 
March 1999.
Patients were recruited following referral by their GP, other clinicians, or by self-referral in
response to an article about the study in a local newspaper (see Appendix 3.1). They were
considered for the study if, for a period of at least the previous six months, they had
exhibited at least three of the following common signs or symptoms of hypothyroidism, for
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which no other cause could be elicited: tiredness; lethargy; weight gain or inability to lose
weight; cold intolerance; hair loss; and dry skin or dry hair. All patients (with the exception
of one) had thyroid function tests, free T4 (FT4) and thyroid stimulating hormone (TSH),
within the reference range (9 - 25pmol/litre) and (0.1 - 5.0mU/litre) respectively. One
patient had a basal TSH of 5.3mU/litre which was subsequently 4.6mU/litre following
treatment with placebo. Normal full blood count, electrolyte and liver function tests were
also a prerequisite of recruitment. Persons with known cardiovascular disease, hepato/renal
failure, pregnancy or thyroid dysfunction were excluded.
A total of 25 patients were enrolled, and 22 patients completed the study. There were 19 
age and sex-matched controls who were normal volunteers; mainly hospital personnel. An
attempt was made to have an equal number of patients and control subjects, however, 
difficulty was experienced in the recruitment of controls. A description of the study
subjects is given in Table 1. One patient withdrew from the study during the first treatment 
period because she was concerned about the dosage, another failed to attend her second 
appointment for no known reason, and a third withdrew from the study due to illness.
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TABLE 1. Baseline Characteristics of the Study Subjects
Patients
(n=22)
Controls
(n=19)
Sex:
Male 2 (9%) 2 (10%)
Female 20 (91%) 17 (90%)
Age 48.45 ±11.2 48.94 ± 10.4
Previous Psychiatric Contact (no.) 6 (27.3%) 1 (5.3%)
Referrer:
GP 12 (54.5%) N/A
Self -  Referral 13 (36.4%)
Other 2 (9.1%)
T4 Previously Prescribed 3 (13.6%) 0
Study Protocol
The Pharmacy Department randomised both patients and control subjects to receive either
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thyroxine or placebo first. This randomisation to treatment order was determined by the
toss of a coin at the first clinic visit. Eight patients and eleven control subjects received
thyroxine first followed by placebo, while the remaining fourteen patients and eight control
subjects received placebo first followed by thyroxine. The randomisation procedure
ensured that all researchers were blind to treatment order allocation until the last participant
had completed the treatment protocol.
The biochemical measures recorded at baseline and on return visits after 12 and 30 weeks,
are given in Appendix 4.2. In order to assess psychological responses to either thyroxine or 
placebo, a range of psychological assessment measures, detailed below, were administered 
at baseline and repeated at return visits. Each participant received either placebo or
thyroxine (lOOpg) for 12 weeks followed by a six week washout period. They then
crossed-over and received a further 12 weeks of treatment. The thyroxine and placebo
tablets were visually identical.
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Psychological Assessment Measures
The following psychological assessment measures were administered to assess quality of life 
concepts: Hospital Anxiety and Depression Scale (HADS)12 to assess emotional disorder; 
Social Functioning Questionnaire (SF-36)13a multi-item scale measuring seven health 
concepts; and Fatigue Scale14 to measure the severity of fatigue. A number of cognitive 
tests were administered: the Digit Span, Logical Memory, Visual Reproduction and Verbal 
Paired Associates subtests from the Wechsler Memory Scale - Revised (WMS-R)15, to 
assess attention and concentration, verbal memory and visual memory respectively. The 
Trail Making Test16 was administered to assess attention, sequencing, mental flexibility and 
motor function. A more detailed description of each assessment measure is given in 
Appendix 3.2.
Two patients failed to complete a page of the SF-36 questionnaire. The missing values on 
these questions were calculated by taking the mean of their scores on the remaining two
visits.
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Statistical Analysis
The period effect was checked by paired t-tests to determine whether the patients
underlying condition and ability to respond remained unchanged from first to second
treatment periods. The carry-over effect was checked by independent t-tests to determine
whether a response to one treatment was different in period one, as compared to period
two.
Independent t-tests were conducted to determine whether there were significant differences 
between patients and control subjects on baseline psychological assessment scores,
following appropriate tests and remedies for normality that were repeated throughout as
necessary.
Psychological assessment scores were collated based on the type of treatment. Paired t-
tests were then applied to the patients’ and control subjects’ scores separately, to determine
whether to accept or reject the null hypothesis that patients’ psychological assessment
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scores would be no better when treated with thyroxine.
All statistical analyses were performed on a personal computer with the statistical package 
SPSS for Windows17.
RESULTS
Prior to testing the main experimental hypothesis, baseline characteristics were tested for 
differences. There were no significant differences in the frequency of group membership for 
patients and controls (x2 = .220, df = 1, P = .639). There was no significant difference 
between mean ages of patients and control subjects (t = -.145, df = 39, P = .885). Finally, 
there were no significant differences for frequency of previous psychiatric contact between 
the two groups (Fisher’s Exact Sig. (2-sided) = .099). In addition, paired samples t-tests 
between all dependent variables at visit two and three indicated the absence of a period 
effect. Independent samples t-test on all dependent variables indicated that there was no 
carry-over effect.
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TABLE 2. Scores on psychological assessment measures at baseline for patients and controls
PATIENTS 
Mean ± SD
CONTROLS 
Mean ± SD t df P value
Logical Memory I 18.68 ± 5.88 29.11+ 6.03 -5.60 39 .000*
Verbal Paired Associates I 15.86 ± 3.54 19.00+ 3.00 -3.04 39 ns
Visual Reproduction I 30.00 ± 6.58 33.89+ 3.81 -2.27 39 ns
Digits Forward 8.55 ± 1.57 9.00+ 2.31 -.746 39 ns
Digits Backward 6.95 ± 2.30 8.11+ 2.79 -1.45 39 ns
Logical Memory 11 15.09+ 6.58 25.63+ 7.60 -.4.80 39 .000*
Verbal Paired Associates II 6.45 ± 1.34 6.95+ 1.18 -1.24 39 ns
Visual Reproduction II 25.32+ 7.07 31.74+ 5.82 -3.14 39 ns
Trail Making Test 97.50 ± 39.97 61.68 + 16.99 3.82A 29.21 .001*
HADS 20.91 ± 8.74 8.37+ 5.04 5.72A 34.33 .000*
Fatigue Scale 30.50 ± 8.79 15.79+ 3.39 7.25A 27.90 .000*
SF-36 Health Survey: 
Physical Functioning (PF) 35.91 +30.69 87.50 + 18.62 -6.60A 35.24 .000*
Role Physical (RP) 13.64 + 30.06 84.21 +26.63 -7.82 39 .000*
Bodily Pain (BP) 37.32 ± 26.92 85.90 + 17.88 -6.70 39 .000*
General Health (GH) 37.50 + 24.10 84.79 ± 14.08 -7.51 39 .000*
Vitality (V) 26.60 + 22.06 64.47 + 17.79 -5.99 39 .000*
Social Functioning (SF) 36.93 + 32.61 91.45 ± 16.69 -6.90 32.22 .000*
Role Emotional (RE) 33.33+44.84 82.45 + 35.78 -3.83 39 .000*
Mental Health (MH) 60.00 + 21.42 75.37 + 16.56 -2.54 39 ns
+ P values were calculated by Independent t-tests
A Equality of variance not assumed by Levene’s Test for Equality of Variances 
Bonferroni Inequality Adjustment applied (P< .0026 for .05 level) * significant at .05 level
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At baseline, patients’ scores on 12 out of 19 psychological measures were significantly 
impaired in comparison to control subject scores (P< 05) (see Table 2.).
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TABLE 3. Comparison of Scores for Patients on Placebo and Thyroxine
PATIENTS
PLACEBO 
Mean ± SD
THROXINE 
Mean ± SD t df P value
Logical Memory I 25.41 + 6.94 24.82+ 6.60 -.768 21 ns
Verbal Paired Associates I 19.23+ 4.06 19.82+ 2.80 .804 21 ns
Visual Reproduction I 32.05 ± 5.69 29.91+ 6.73 -5.260 21 Ooo*81**
Digits Forward 9.00 ± 1.85 9.54+ 1.40 1.779 21 ns
Digits Backward 7.68+ 1.99 7.86+ 2.17 .392 21 ns
Logical Memory II 21.00 ± 1.49 21.82+ 7.90 .643 21 ns
Verbal Paired Associates II 6.86 ± 1.32 6.83+ 1.44 -.176 21 ns
Visual Reproduction n 26.86 ± 7.58 27.36+ 7.51 .473 21 ns
Trail Making Test 79.95 ± 30.52 81.32 + 31.06 .290 21 ns
HADS 14.64 ± 8.36 14.77+ 10.01 .062 21 ns
Fatigue Scale 
SF-36
12.86 ± 9.40 15.32 + 10.55 .648 21 ns
Physical Functioning (PF) 54.91 + 34.20 46.14 + 32.10 .036 21 ns
Role Physical (RP) 43.18 ± 40.22 36.36 + 41.35 -.597 21 ns
Bodily Pain (BP) 44.55 ± 28.53 47.77 ± 27.84 .532 21 ns
General Health (GH) 48.00 + 24.24 42.02+24.24 -1.257 21 ns
Vitality (V) 41.82 + 28.14 36.14 + 26.94 -.662 21 ns
Social Functioning (SF) 55.68 + 34.01 56.25 + 31.52 .006 21 ns
Role Emotional (RE) 63.62+43.53 48.47 + 46.83 -1.11 21 ns
Mental Health (MH) 65.09 + 21.92 61.64 + 26.44 -.571 21 ns
+ P values were calculated by paired t-tests 
trans t-test using transformed variables
Bonferonni Inequality Adjustment applied (P < .002 for cc=.01 level) 
♦significant at .05 level
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TABLE 4. Comparison of scores for Controls Subjects on Placebo and Thyroxine
CONTROLS
PLACEBO 
Mean ±SD
THYROXINE 
Mean ± SD t df P value
Logical Memory I 33.10 ± 5.90 34.00+ 4.69 .773 18 ns
Verbal Paired Associates I 21.00 ± 2.73 28.32+ 2.80 -1.753 18 ns
Visual Reproduction I 35.63+ 2.50 34.68 ± 3.51 -1.710 18 ns
Digits Forward 9.80 ± 2.25 9.63 + 1.86 -.459 18 ns
Digits Backward 8.74 ± 2.08 8.26+ 2.70 -1.184 18 ns
Logical Memory n 30.63 ± 6.36 31.42 ± 7.00 .689 18 ns
Verbal Paired Associates n 7.42+ 1.02 7.26 ± 1.05 1.244 18 ns
Visual Reproduction II 34.42+ 3.60 34.50 + 3.70 .068 18 ns
Trail Making Test 54.20 ± 12.42 57.05 ±19.16 1.058 18 ns
HADS 6.32 ± 4.60 8.63 ± 6.52 1.878 18 ns
Fatigue Scale 12.00+ 3.80 15.32 ± 3.30 -29.543 18 .000trans*
SF-36 Health Survey: 
Physical Functioning (PF) 92.63 ± 9.63 91.00 + 14.20 .681 18 ns
Role Physical (RP) 89.47+19.21 79.00 + 26.70 -1.407 18 ns
Bodily Pain (BP) 82.53 ± 24.30 80.00 + 18.35 -.937 18 ns
General Health (GH) 84.05 ± 10.40 79.74 + 12.21 -1.518 18 ns
Vitality (V) 73.42 + 15.64 60.00 ± 16.83 -3.258 18 ns
Social Functioning (SF) 94.10 ± 14.05 86.16 + 18.11 3.793 18 .001trans*
Role Emotional (RE) 91.70 ± 19.50 82.44 ± 28.05 4.180 18 © o h"i
'
Mental Health (MH) 79.20 ± 12.41 78.10 + 15.00 -0.388 18 ns
+ P values were calculated by paired t-tests 
413113 paired t-test using transformed variables 
Bonferroni Inequality Adjustment applied (p < .002 for a=.05 level) 
‘significant at .05 level
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In comparing the effects of treatment, paired t-tests for patients’ scores on thyroxine and 
placebo indicated that only one psychological measure was significantly different. Patients’ 
mean scores on Visual Reproduction (Immediate Recall) were significantly greater on 
placebo (P<001) (see Table 3). In a comparison of control subjects’ scores on thyroxine 
versus placebo, three psychological measures (Fatigue Scale14, SF-36 Social Functioning 
and Role Emotional13) were significantly different, with impaired functioning on thyroxine 
(see Table 4).
DISCUSSION
In terms of the treatment effect, psychological assessment scores of subjects on thyroxine in
comparison to placebo indicate that thyroxine does not benefit patients or control subjects.
Patients had a significantly impaired visual reproduction (immediate recall) score when
treated with thyroxine. Control subjects had significantly impaired scores with regards to
fatigue, social and emotional functioning when taking thyroxine. It is possible that because
subjects (with the exception of one person) had normal levels of free T4 in the first instance,
for some, thyroxine treatment raised their free T4 level to the extent that they began to
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experience symptoms consistent with the high level of free T4 found in hyperthyroidism.
These symptoms include nervousness, irritability, emotional lability and fatigue that could
conceivably have had an impact on these scores. Therefore, the null hypothesis that
patients’ psychological assessment scores would be no better when treated with thyroxine is
accepted.
There are no known experimental studies involving symptomatically hypothyroid but 
biochemically euthyroid patients. A comparison can, therefore, only be made to findings 
from studies of patients with hypothyroidism and subclinical hypothyroidism and to the
recent correspondence in the BMJ detailing clinicians’ observations of individual patients’
responses to thyroxine in the clinic setting. The cognitive functioning, physical and mental
health of the patients in this study did not benefit from thyroxine treatment. Thyroxine
actually made some subjects function more poorly in certain areas. This is inconsistent with
previous research that has demonstrated improvements following thyroxine treatment in 
patients with hypothyroidism and subclinical hypothyroidism..6,9,18,19 In addition, these
findings question whether the two symptomatically hypothyroid but biochemically euthyroid 
patients, observed by McLaren, Kelly and Pollock4, who reported a marked improvement in
their condition, felt better due to thyroxine treatment.
Analysis of the psychological assessment measures at baseline show that patients were
significantly more impaired than control subjects on the majority of measures. Again, a 
comparison can only be made to findings from studies of patients with hypothyroidism and 
subclinical hypothyroidism. This finding is consistent with previous research that found that 
patients experiencing hypothyroidism and subclinical hypothyroidism frequently experienced 
depressive symptoms, physical complaints, fatigue, psychomotor speed and impairment of 
recent memory.6,7,9 The patients in this study did not have attention and concentration 
difficulties. However, Mennemier, Gamer and Heilman20 suggest that concentration may be
one of the cognitive functions least affected by hypothyroidism.
The strengths of this study include the randomised design, careful attention to double
blinding and a comprehensive set of valid and reliable psychological assessment measures. 
A control group was included who were well matched on a range of potentially
confounding variables such as sex and age. There was no significant difference between
patients and control groups with regards to previous psychiatric contact. Also, this study
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had an adequate washout period. In some previous studies of hypothyroidism and
subclinical hypothyroidism, psychological assessment measures have not been standardised,
a narrow range of cognitive functions have been assessed or a control group, placebo or
adequate washout period have not been included (see Chapter 2, Major Research Project
Literature Review, for a full discussion).
Nonetheless, this is a preliminary study that has some limitations. These patients may have 
some other disorder that was not adequately assessed and could have necessitated exclusion 
from the study. It is possible that some of the patients may have suffered from Chronic 
Fatigue Syndrome, as the symptomatology of this syndrome and hypothyroidism overlap.
A small number of patients reported that they felt better on thyroxine and in certain cases
this was reflected in an improvement in their psychological assessment scores. It is possible
that some symptomatically hypothyroid but biochemically euthyroid patients will respond to 
thyroxine, but, the heterogeneous nature of the patient group in this study, in conjunction 
with the relatively small sample size, meant that this was not reflected in the analysis of
psychological assessment scores.
A further consideration is the possibility that thyroxine was not the most appropriate drug
with which to treat these patients. A recent study concluded that in patients with
hypothyroidism, partial substitution with triiodothyronine (T3, the active thyroid hormone) 
for thyroxine might improve mood and neuropsychological function.21 It may be that the
present study should be replicated with a larger sample size and this combination of
treatment.
In conclusion, this first known randomised, double blind, placebo-controlled trial
demonstrates that symptomatically hypothyroid but biochemically euthyroid patients share
some, but not all, of the impairments in psychological wellbeing and cognitive function of
hypothyroid and subclinical hypothyroid patients. However, this is possibly where the
similarity ends. Symptomatically hypothyroid but biochemically euthyroid patients do not
appear to benefit from treatment with thyroxine on a wide range of psychological and
cognitive measures. It is suggested that there is no empirical evidence to justify the routine
prescription of thyroxine to this group of patients.
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Psychological intervention with parents of a child experiencing cyclical vomiting
syndrome: A single case study
ABSTRACT
In the absence of a consensus regarding the aetiology and psychological management of 
severe cyclical vomiting syndrome (CVS) in childhood, application of the ‘illness network 
model’ (Lask and Fosson, 1989), normally concerned with more common childhood 
psychogenic disorders, was applied to this case. Intervention guided by this model aimed 
to reduce cyclical vomiting associated hospital admissions, by training parents in the 
application of behavioural modification techniques to the child’s disturbed behaviour. 
However, it is postulated that intervention to reduce parental psychological distress and 
maladaptive family communication, commonly associated with having a CVS child, is a 
necessary adjunct to reducing cyclical vomiting behaviours than behaviour modification 
alone. Although hospital admissions were reduced, the continuing severity of childhood 
disturbance and parental distress highlights limited prognosis with this severely debilitating 
and rare disorder.
KEYWORDS
Cyclical vomiting syndrome, Child, Family, Psychological Management, Parenting 
Distress
Cognitive-behaviour therapy and adolescent depression: A single case study
ABSTRACT
The quality of family relationships have a significant bearing on the development and 
maintenance of adolescent depression (Sochet and Dadds, 1997). In the absence of 
empirical evidence regarding the efficacy of family involvement in cognitive-behaviour 
therapy (CBT) approaches to adolescent depression, this case indicates that it is possible to 
resolve clinically significant depression by applying the principles of CBT, against a 
background of chronic family dysfunction.
KEY WORDS: adolescent depression, treatment, cognitive-behaviour therapy, family 
conflict.
Adolescent traumatic head injury and school reintegration: A single case study
ABSTRACT
Severe traumatic head injury causes extreme changes in the life of the injured person; 
affecting a large number of activities and functions in different life domains (Florian, Katz 
and Lahav, 1991). In terms of school reintegration following injury, the primary goal is to 
ensure academic and social success for the young person (Ylvisaker et al., 1991). The 
following case presentation indicates how neuropsychological assessment can practically 
inform school reintegration and future educational provision for a head injured adolescent.
KEY WORDS head injury, adolescence, school reintegration.
APPENDICES
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